Business Wire

MO-VERNE-GLOBAL

15.11.2021 14:02:11 CET | Business Wire | Press release

Share
D9-backed Verne Global Invests $50m to Expand Data Center Campus by 10MW

Verne Global , provider of sustainable data center solutions for high intensity computing, recently acquired by Digital 9 Infrastructure plc (D9), today announced that it is expanding its 40-acre data center campus by a further 10MW of constructed power capacity. The expansion is backed by D9, the investment trust that focuses on sustainable digital infrastructure assets, which will fund the $50m development of new enterprise-class data center space.

Ideally located with access to abundant, low-cost renewable energy and a highly reliable national electrical grid, the Icelandic data center company continues to attract a range of enterprise customers as demand for high intensity compute sees sustained growth across industries. As more companies look to decarbonize their digital infrastructure by powering intensive applications such as artificial intelligence, mathematical modelling and predictive analytics with cleaner, greener energy, Verne Global is expanding now to meet contracted demand. The data center company’s best-in-class onsite technical and operations team will continue to use its specialized expertise to work around the clock to support and optimize the high density environments and workloads it houses.

“We’re seeing sector after sector looking to move into high performance analytics environments and it’s exciting to scale our campus again alongside new and existing customers to meet that need,” said Dominic Ward, CEO at Verne Global. “It’s great to also take this first step into the future as part of the D9 Infrastructure platform, and we are all eagerly looking forward to what comes next.”

“We are proud to support Verne Global and play a part in bringing its vision for the future into reality,” said Thor Johnsen, Head of Digital Infrastructure at Triple Point, D9’s investment manager. “Powered by Iceland’s abundant green power, Verne Global’s expanded data center will be even better placed to provide resilient digital infrastructure that offers a true reduction in carbon emissions for its customers alongside long-term economic and sustainable stability.”

As part of this expansion, Verne Global is partnering with Integra Mission Critical , the modular data center solutions provider, to optimize its delivery of sustainable high intensity compute at scale while fitting out the new data center space. Utilizing Integra’s solution-driven engineering expertise to implement modular data center infrastructure will allow Verne Global to increase sustainability measures in line with its core mission, while promoting scalability and safety, and decreasing cost.

“Verne Global’s facility has been built from the ground up for highly specialist data center services that are sustainable, scalable and bespoke,” said John Kolar, Principal at Integra Mission Critical. “These mutual principles make our companies a natural fit and we’re so excited to be teaming up and putting our decades of experience in solution-driven engineering to good use to provide a quality turnkey infrastructure solution for the new space.”

SC21 delegates can visit Verne Global at the Data Centers by Iceland stand (#1819) at SC21 in St Louis, MO, 15-19 November, 2021.

About Verne Global

Verne Global delivers data center solutions for high intensity computing, engineered for optimal high performance compute and built upon 100% renewable energy. Our clean grid and stable climate cuts costs and energy usage, and our expert team provides on-site, around-the-clock support to maximize performance and flexibility for customer workloads.

Founded in 2012, our Icelandic data center campus powers some of the world’s most innovative and demanding industries, including financial services, earth sciences, life sciences, engineering, scientific research and AI.

About Integra Mission Critical

Integra Mission Critical delivers modular mechanical, electrical and plumbing (MEP) solutions for the mission critical sector. With in-house manufacturing facilities throughout the United States, Europe, and Asia, Integra Mission Critical has a global reach with a local focus. Our solutions-driven engineering enables us to meet each customer’s specific needs across the globe, whether that be specialized cooling for a specific climate, or sustainable solutions for backup power generation.

Integra Mission Critical leverages innovative designs and an integrated approach and combines them with our relentless passion to mitigate risk, compress the schedule, reduce costs, and close the gap between capex and revenue generation.

Founded in 2014, with a focus on cooling solutions, Integra Mission Critical has since expanded into electrical solutions (2017), ranging from electrical skids to modular electrical rooms, to complete modular data centers. Our North America headquarters are in Dallas, Texas with our European headquarters in London, England.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye